EA201071103A1 - Способ получения порошковых композиций орлистата - Google Patents

Способ получения порошковых композиций орлистата

Info

Publication number
EA201071103A1
EA201071103A1 EA201071103A EA201071103A EA201071103A1 EA 201071103 A1 EA201071103 A1 EA 201071103A1 EA 201071103 A EA201071103 A EA 201071103A EA 201071103 A EA201071103 A EA 201071103A EA 201071103 A1 EA201071103 A1 EA 201071103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
orlistat
powder compositions
obtaining powder
pharmaceutical compositions
relates
Prior art date
Application number
EA201071103A
Other languages
English (en)
Inventor
Ярослав Мазгальский
Анна Шемецка-Голябек
Анна Каминская
Original Assignee
Закляды Фармацеутичне Полфарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закляды Фармацеутичне Полфарма Са filed Critical Закляды Фармацеутичне Полфарма Са
Publication of EA201071103A1 publication Critical patent/EA201071103A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к новому способу изготовления стабильных, отвечающих соответствующим требованиям к качеству, фармацевтических композиций в форме инкапсулированного порошка, содержащих орлистат и фармацевтически приемлемые вспомогательные вещества. Изобретение также относится к фармацевтическим композициям орлистата в форме инкапсулированного порошка, полученным в соответствии со способом согласно настоящему изобретению.
EA201071103A 2008-03-20 2009-03-19 Способ получения порошковых композиций орлистата EA201071103A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL384756A PL216542B1 (pl) 2008-03-20 2008-03-20 Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
PCT/PL2009/000025 WO2009116880A2 (en) 2008-03-20 2009-03-19 Process for obtaining powder compositions of orlistat

Publications (1)

Publication Number Publication Date
EA201071103A1 true EA201071103A1 (ru) 2011-02-28

Family

ID=41055345

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071103A EA201071103A1 (ru) 2008-03-20 2009-03-19 Способ получения порошковых композиций орлистата

Country Status (8)

Country Link
US (1) US20110045085A1 (ru)
EP (2) EP2268266B1 (ru)
DK (1) DK2268266T3 (ru)
EA (1) EA201071103A1 (ru)
ES (1) ES2836736T3 (ru)
PL (1) PL216542B1 (ru)
PT (1) PT2268266T (ru)
WO (1) WO2009116880A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) * 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
WO2012082083A1 (en) * 2010-12-15 2012-06-21 Les Laboratoires Medis Sa Pharmaceutical formulation containing tetrahydrolipstatin as an active ingredient

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE10021618A1 (de) 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
PL203804B1 (pl) 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
WO2003047531A2 (en) * 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
CL53426B (ru) * 2007-08-06 2016-11-28
EA201070378A1 (ru) 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size

Also Published As

Publication number Publication date
PL216542B1 (pl) 2014-04-30
EP3682869A1 (en) 2020-07-22
EP2268266B1 (en) 2020-10-21
DK2268266T3 (da) 2020-11-02
EP2268266A2 (en) 2011-01-05
US20110045085A1 (en) 2011-02-24
PL384756A1 (pl) 2009-09-28
WO2009116880A3 (en) 2009-12-10
WO2009116880A2 (en) 2009-09-24
PT2268266T (pt) 2020-12-18
ES2836736T3 (es) 2021-06-28

Similar Documents

Publication Publication Date Title
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
MX348823B (es) Formulaciones estables de linaclotida.
MY181898A (en) Heterocyclic compounds and uses thereof
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
MX2010004028A (es) 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
GB2501219A (en) Orally bioavailable peptide drug compositions and methods thereof
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.